Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary

Tom Huizinga; Peter Nigrovic; Eric Ruderman; Hendrik Schulze-Koops

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary

Tom Huizinga^*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	98-99
Number of pages	2
Journal	International Journal of Advances in Rheumatology
Volume	9
Issue number	3
State	Published - 2011

ASJC Scopus subject areas

Rheumatology

Cite this

Huizinga, T., Nigrovic, P., Ruderman, E., & Schulze-Koops, H. (2011). Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary. International Journal of Advances in Rheumatology, 9(3), 98-99.

Huizinga, Tom ; Nigrovic, Peter ; Ruderman, Eric et al. / Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate : Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary. In: International Journal of Advances in Rheumatology. 2011 ; Vol. 9, No. 3. pp. 98-99.

@article{4c7cff43b1bc49659f80bb66cf8c8710,

title = "Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary",

author = "Tom Huizinga and Peter Nigrovic and Eric Ruderman and Hendrik Schulze-Koops",

year = "2011",

language = "English (US)",

volume = "9",

pages = "98--99",

journal = "International Journal of Advances in Rheumatology",

issn = "1478-856X",

publisher = "Remedica Medical Education and Publishing Ltd",

number = "3",

}

Huizinga, T, Nigrovic, P, Ruderman, E & Schulze-Koops, H 2011, 'Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary', International Journal of Advances in Rheumatology, vol. 9, no. 3, pp. 98-99.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary. / Huizinga, Tom; Nigrovic, Peter; Ruderman, Eric et al.
In: International Journal of Advances in Rheumatology, Vol. 9, No. 3, 2011, p. 98-99.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate

T2 - Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary

AU - Huizinga, Tom

AU - Nigrovic, Peter

AU - Ruderman, Eric

AU - Schulze-Koops, Hendrik

PY - 2011

Y1 - 2011

UR - http://www.scopus.com/inward/record.url?scp=84863818281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863818281&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:84863818281

SN - 1478-856X

VL - 9

SP - 98

EP - 99

JO - International Journal of Advances in Rheumatology

JF - International Journal of Advances in Rheumatology

IS - 3

ER -

Huizinga T, Nigrovic P, Ruderman E, Schulze-Koops H. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary. International Journal of Advances in Rheumatology. 2011;9(3):98-99.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary

ASJC Scopus subject areas

Other files and links

Cite this